Cargando…

Tocilizumab does not block interleukin-6 (IL-6) signaling in murine cells

Tocilizumab is a humanized monoclonal antibody that is approved for the treatment of different human inflammatory diseases, including rheumatoid arthritis and cytokine release syndrome. Tocilizumab binds to the interleukin-6 receptor (IL-6R) and thereby blocks signaling of the pro-inflammatory cytok...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lokau, Juliane, Kleinegger, Florian, Garbers, Yvonne, Waetzig, Georg H., Grötzinger, Joachim, Rose-John, Stefan, Haybaeck, Johannes, Garbers, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7197771/ https://www.ncbi.nlm.nih.gov/pubmed/32365119 http://dx.doi.org/10.1371/journal.pone.0232612

Ejemplares similares

A single aromatic residue in sgp130Fc/olamkicept allows the discrimination between interleukin-6 and interleukin-11 trans-signaling
por: Lokau, Juliane, et al.
Publicado: (2021)

Jak-Stat Signaling Induced by Interleukin-6 Family Cytokines in Hepatocellular Carcinoma
por: Lokau, Juliane, et al.
Publicado: (2019)

Interleukin-6 controls recycling and degradation, but not internalization of its receptors
por: Flynn, Charlotte M., et al.
Publicado: (2021)

Cathepsin S provokes interleukin-6 (IL-6) trans-signaling through cleavage of the IL-6 receptor in vitro
por: Flynn, Charlotte M., et al.
Publicado: (2020)

Generation of Soluble Interleukin-11 and Interleukin-6 Receptors: A Crucial Function for Proteases during Inflammation
por: Lokau, Juliane, et al.
Publicado: (2016)

Cleavage Site Localization Differentially Controls Interleukin-6 Receptor Proteolysis by ADAM10 and ADAM17
por: Riethmueller, Steffen, et al.
Publicado: (2016)

Recombinant p35 from Bacteria Can Form Interleukin (IL-)12, but Not IL-35
por: Aparicio-Siegmund, Samadhi, et al.
Publicado: (2014)

Activation of Toll-like Receptor 2 (TLR2) induces Interleukin-6 trans-signaling
por: Flynn, Charlotte M., et al.
Publicado: (2019)

Coding variants of the interleukin-11 receptor with reduced protein maturation show protease-dependent trans-signaling and transduce normal STAT3 signaling
por: Kespohl, Birte, et al.
Publicado: (2022)

Joint Reconstituted Signaling of the IL-6 Receptor via Extracellular Vesicles
por: Arnold, Philipp, et al.
Publicado: (2020)

Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19
por: Garbers, Christoph, et al.
Publicado: (2021)

Anti–IL-6 cytokine treatment has no impact on elevated hematocrit or splenomegaly in a polycythemia vera mouse model
por: Baldauf, Conny K., et al.
Publicado: (2022)

Interleukin-11 receptor expression on monocytes is dispensable for their recruitment and pathogen uptake during Leishmania major infection
por: Baars, Iris, et al.
Publicado: (2021)

Erratum: Control of ADAM17 activity by regulation of its cellular localisation
por: Lorenzen, Inken, et al.
Publicado: (2016)

Control of ADAM17 activity by regulation of its cellular localisation
por: Lorenzen, Inken, et al.
Publicado: (2016)

Perturbation of the Actin Cytoskeleton in Human Hepatoma Cells Influences Interleukin-6 (IL-6) Signaling, but Not Soluble IL-6 Receptor Generation or NF-κB Activation
por: Georgieva, Elizabeta, et al.
Publicado: (2021)

Differences in Shedding of the Interleukin-11 Receptor by the Proteases ADAM9, ADAM10, ADAM17, Meprin α, Meprin β and MT1-MMP
por: Sammel, Martin, et al.
Publicado: (2019)

Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role of N-Glycosylation
por: Riethmueller, Steffen, et al.
Publicado: (2017)

The metalloprotease ADAM10 generates soluble interleukin-2 receptor alpha (sCD25) in vivo
por: Kirschke, Sophia, et al.
Publicado: (2022)

Meprin Metalloproteases Generate Biologically Active Soluble Interleukin-6 Receptor to Induce Trans-Signaling
por: Arnold, Philipp, et al.
Publicado: (2017)

Soluble interleukin-6 receptor in patients with JAK2V617F somatic mutation and myeloproliferative neoplasm
por: Garbers, Christoph, et al.
Publicado: (2020)

Natural Glycoforms of Human Interleukin 6 Show Atypical Plasma Clearance
por: Reif, Andreas, et al.
Publicado: (2021)

IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome
por: Dufranc, Etienne, et al.
Publicado: (2020)

Interleukin-6, but not the interleukin-6 receptor plays a role in recovery from dextran sodium sulfate-induced colitis
por: SOMMER, JAN, et al.
Publicado: (2014)

Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases
por: Nikolaus, Susanna, et al.
Publicado: (2018)

Targeting IL-6 trans-signalling: past, present and future prospects
por: Rose-John, Stefan, et al.
Publicado: (2023)

Case Report: Arterial Wall Inflammation in Atherosclerotic Cardiovascular Disease is Reduced by Olamkicept (sgp130Fc)
por: Schulte, Dominik M., et al.
Publicado: (2022)

Interleukin-6 blockade with tocilizumab in COVID-19: Does it live up to its hype?
por: Kow, C.S., et al.
Publicado: (2021)

The correlations of serum interleukin-6 (il-6) levels and serum soluble il-6 receptor levels with disease activity in systemic juvenile idiopathic arthritis patients with and without tocilizumab treatment
por: Lerkvaleekul, Butsabong, et al.
Publicado: (2014)

Special issue on Interleukin-6 (IL-6)
por: Rincon, Mercedes
Publicado: (2012)

Transgenic inhibition of interleukin-6 trans-signaling does not prevent skeletal pathologies in mucolipidosis type II mice
por: Westermann, Lena Marie, et al.
Publicado: (2021)

Interleukin-6 receptor specific RNA aptamers for cargo delivery into target cells
por: Meyer, Cindy, et al.
Publicado: (2012)

Pharmacological inhibition of IL-6 trans-signaling improves compromised fracture healing after severe trauma
por: Kaiser, Kathrin, et al.
Publicado: (2018)

The Synthetic Retinoid Acitretin Increases IL-6 in the Central Nervous System of Alzheimer Disease Model Mice and Human Patients
por: dos Santos Guilherme, Malena, et al.
Publicado: (2019)

Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy
por: Patel, Aarat M, et al.
Publicado: (2010)

Tocilizumab, a Proposed Therapy for the Cachexia of Interleukin6-Expressing Lung Cancer
por: Ando, Katsutoshi, et al.
Publicado: (2014)

Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19
por: Gade, Akhil R., et al.
Publicado: (2020)

Serum interleukin-6 in seropositive rheumatoid arthritis and response to tocilizumab: An observational study
por: Kumar, Abhishek, et al.
Publicado: (2022)

Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6
por: Flisiak, Robert, et al.
Publicado: (2021)

SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the ‘culprit lesion’ of ARDS onset? What is there besides Tocilizumab? SGP130Fc
por: Magro, Giuseppe
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e3vifkm5dg08c9oc7uie2u3gc2